In April 2008, KRAS mutation was reported to be a negative predictive biomarker for EGFR targeted therapy—retrospective analysis of a randomised trial1 of panitumumab versus supportive care showed that panitumumab benefit was confined to patients with tumours wild-type at KRAS codons 12–13 (p<0·0001). The gene discussed is KRAS; the disease is neoplasm.